Shopping Cart 0
Cart Subtotal
AED 0

Progenics Pharmaceuticals Inc (PGNX) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 1376

Details

Progenics Pharmaceuticals Inc (PGNX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Progenics Pharmaceuticals Inc (Progenics) is a biopharmaceutical company that develops and commercializes innovative targeted medicines to find, fight and follow cancer including therapeutic agents to treat cancer. Its products include Azedra, in treating unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma and Relistor in treatment of opioid-induced constipation. The company's pipeline products include PyL (18F-DCFPyL) imaging agent for prostate cancer, 1095 (I 131 1095) and PSMA-TTC both of which are prostate specific membrane antigen (PSMA) being evaluated in treatment of metastatic prostate cancer. The company sells its products through distribution, co-promotion, co-marketing, or licensing arrangements with third parties for territories outside the U.S. Progenics is headquartered in New York, the US.

Progenics Pharmaceuticals Inc Key Recent Developments

Sep 18,2019: Velan launches consent solicitation to reconstitute the Progenics board with its five highly-qualified, independent director nominees

Sep 18,2019: Progenics confirms notice of preliminary consent solicitation by Velan Capital, L.P. despite repeated efforts by the company to reach a reasonable resolution

Aug 09,2019: Progenics Pharmaceuticals announces second quarter 2019 financial results and business update

Jul 08,2019: Progenics Pharmaceuticals strengthens management team with appointment of Huw Jones as Vice President, Commercial

Jul 08,2019: Progenics urges shareholders to vote today FOR the highly qualified director candidates on the WHITE Proxy Card

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Progenics Pharmaceuticals Inc-Key Facts

Progenics Pharmaceuticals Inc-Key Employees

Progenics Pharmaceuticals Inc-Key Employee Biographies

Progenics Pharmaceuticals Inc-Major Products and Services

Progenics Pharmaceuticals Inc-History

Progenics Pharmaceuticals Inc-Company Statement

Progenics Pharmaceuticals Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Progenics Pharmaceuticals Inc-Business Description

Progenics Pharmaceuticals Inc-SWOT Analysis

SWOT Analysis-Overview

Progenics Pharmaceuticals Inc-Strengths

Progenics Pharmaceuticals Inc-Weaknesses

Progenics Pharmaceuticals Inc-Opportunities

Progenics Pharmaceuticals Inc-Threats

Progenics Pharmaceuticals Inc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Progenics Pharmaceuticals Inc, Recent Deals Summary

Section 5-Company's Recent Developments

Sep 18, 2019: Velan launches consent solicitation to reconstitute the Progenics board with its five highly-qualified, independent director nominees

Sep 18, 2019: Progenics confirms notice of preliminary consent solicitation by Velan Capital, L.P. despite repeated efforts by the company to reach a reasonable resolution

Aug 09, 2019: Progenics Pharmaceuticals announces second quarter 2019 financial results and business update

Jul 08, 2019: Progenics Pharmaceuticals strengthens management team with appointment of Huw Jones as Vice President, Commercial

Jul 08, 2019: Progenics urges shareholders to vote today FOR the highly qualified director candidates on the WHITE Proxy Card

Jun 28, 2019: Velan clarifies interactions with Progenics Pharmaceuticals' board of directors

Jun 20, 2019: Velan calls on Progenics Pharmaceuticals' board to back up recent claims

May 09, 2019: Progenics Pharmaceuticals announces first quarter 2019 financial results and business update

May 06, 2019: Progenics Pharmaceuticals issues statement regarding Velan Capital

Mar 14, 2019: Progenics Pharmaceuticals announces fourth quarter and full-year 2018 financial results and business update

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Progenics Pharmaceuticals Inc, Performance Chart (2014-2018)

Progenics Pharmaceuticals Inc, Ratio Charts

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Progenics Pharmaceuticals Inc, Key Facts

Progenics Pharmaceuticals Inc, Key Employees

Progenics Pharmaceuticals Inc, Key Employee Biographies

Progenics Pharmaceuticals Inc, Major Products and Services

Progenics Pharmaceuticals Inc, History

Progenics Pharmaceuticals Inc, Subsidiaries

Progenics Pharmaceuticals Inc, Key Competitors

Progenics Pharmaceuticals Inc, Ratios based on current share price

Progenics Pharmaceuticals Inc, Annual Ratios

Progenics Pharmaceuticals Inc, Annual Ratios (Cont...1)

Progenics Pharmaceuticals Inc, Annual Ratios (Cont...2)

Progenics Pharmaceuticals Inc, Interim Ratios

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Progenics Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Progenics Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Shionogi & Co Ltd

Takeda Pharmaceutical Co Ltd

Jazz Pharmaceuticals Plc

Medivation Inc

AstraZeneca Plc

Nektar Therapeutics

Cubist Pharmaceuticals Holdings Inc

Aytu BioScience Inc

Janssen Biotech Inc

Blue Earth Diagnostics Ltd

Company Profile

Company Profile Title

Progenics Pharmaceuticals Inc (PGNX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Progenics Pharmaceuticals Inc (Progenics) is a biopharmaceutical company that develops and commercializes innovative targeted medicines to find, fight and follow cancer including therapeutic agents to treat cancer. Its products include Azedra, in treating unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma and Relistor in treatment of opioid-induced constipation. The company's pipeline products include PyL (18F-DCFPyL) imaging agent for prostate cancer, 1095 (I 131 1095) and PSMA-TTC both of which are prostate specific membrane antigen (PSMA) being evaluated in treatment of metastatic prostate cancer. The company sells its products through distribution, co-promotion, co-marketing, or licensing arrangements with third parties for territories outside the U.S. Progenics is headquartered in New York, the US.

Progenics Pharmaceuticals Inc Key Recent Developments

Sep 18,2019: Velan launches consent solicitation to reconstitute the Progenics board with its five highly-qualified, independent director nominees

Sep 18,2019: Progenics confirms notice of preliminary consent solicitation by Velan Capital, L.P. despite repeated efforts by the company to reach a reasonable resolution

Aug 09,2019: Progenics Pharmaceuticals announces second quarter 2019 financial results and business update

Jul 08,2019: Progenics Pharmaceuticals strengthens management team with appointment of Huw Jones as Vice President, Commercial

Jul 08,2019: Progenics urges shareholders to vote today FOR the highly qualified director candidates on the WHITE Proxy Card

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Progenics Pharmaceuticals Inc-Key Facts

Progenics Pharmaceuticals Inc-Key Employees

Progenics Pharmaceuticals Inc-Key Employee Biographies

Progenics Pharmaceuticals Inc-Major Products and Services

Progenics Pharmaceuticals Inc-History

Progenics Pharmaceuticals Inc-Company Statement

Progenics Pharmaceuticals Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Progenics Pharmaceuticals Inc-Business Description

Progenics Pharmaceuticals Inc-SWOT Analysis

SWOT Analysis-Overview

Progenics Pharmaceuticals Inc-Strengths

Progenics Pharmaceuticals Inc-Weaknesses

Progenics Pharmaceuticals Inc-Opportunities

Progenics Pharmaceuticals Inc-Threats

Progenics Pharmaceuticals Inc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Progenics Pharmaceuticals Inc, Recent Deals Summary

Section 5-Company's Recent Developments

Sep 18, 2019: Velan launches consent solicitation to reconstitute the Progenics board with its five highly-qualified, independent director nominees

Sep 18, 2019: Progenics confirms notice of preliminary consent solicitation by Velan Capital, L.P. despite repeated efforts by the company to reach a reasonable resolution

Aug 09, 2019: Progenics Pharmaceuticals announces second quarter 2019 financial results and business update

Jul 08, 2019: Progenics Pharmaceuticals strengthens management team with appointment of Huw Jones as Vice President, Commercial

Jul 08, 2019: Progenics urges shareholders to vote today FOR the highly qualified director candidates on the WHITE Proxy Card

Jun 28, 2019: Velan clarifies interactions with Progenics Pharmaceuticals' board of directors

Jun 20, 2019: Velan calls on Progenics Pharmaceuticals' board to back up recent claims

May 09, 2019: Progenics Pharmaceuticals announces first quarter 2019 financial results and business update

May 06, 2019: Progenics Pharmaceuticals issues statement regarding Velan Capital

Mar 14, 2019: Progenics Pharmaceuticals announces fourth quarter and full-year 2018 financial results and business update

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Progenics Pharmaceuticals Inc, Performance Chart (2014-2018)

Progenics Pharmaceuticals Inc, Ratio Charts

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Progenics Pharmaceuticals Inc, Key Facts

Progenics Pharmaceuticals Inc, Key Employees

Progenics Pharmaceuticals Inc, Key Employee Biographies

Progenics Pharmaceuticals Inc, Major Products and Services

Progenics Pharmaceuticals Inc, History

Progenics Pharmaceuticals Inc, Subsidiaries

Progenics Pharmaceuticals Inc, Key Competitors

Progenics Pharmaceuticals Inc, Ratios based on current share price

Progenics Pharmaceuticals Inc, Annual Ratios

Progenics Pharmaceuticals Inc, Annual Ratios (Cont...1)

Progenics Pharmaceuticals Inc, Annual Ratios (Cont...2)

Progenics Pharmaceuticals Inc, Interim Ratios

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Progenics Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Progenics Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Shionogi & Co Ltd

Takeda Pharmaceutical Co Ltd

Jazz Pharmaceuticals Plc

Medivation Inc

AstraZeneca Plc

Nektar Therapeutics

Cubist Pharmaceuticals Holdings Inc

Aytu BioScience Inc

Janssen Biotech Inc

Blue Earth Diagnostics Ltd